Secukinumab 150/300 mg Provides Sustained Improvements in...

  • Main
  • 2020 / 01
  • Secukinumab 150/300 mg Provides Sustained Improvements in...

Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3‐Year Results from the Phase 3 MEASURE 3 Study

Pavelka, Karel, Kivitz, Alan J., Dokoupilova, Eva, Blanco, Ricardo, Maradiaga, Marco, Tahir, Hasan, Wang, Yi, Porter, Brian O., Stefanska, Anna, Richards, Hanno B., Rohrer, Susanne
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Language:
english
Journal:
ACR Open Rheumatology
DOI:
10.1002/acr2.11102
Date:
January, 2020
File:
PDF, 311 KB
english, 2020
Conversion to is in progress
Conversion to is failed